原料辞典検索/peg-40-hydrogenated-castor-oil/PEG-40 HYDROGENATED CASTOR OIL
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

PEG-40 HYDROGENATED CASTOR OIL

日本化粧品工業連合会 (JCIA) 表示名称: PEG-40水添ヒマシ油
乳化剤洗浄剤
[EU CosIng Official Definition] Castor oil (Ricinus communis), hydrogenated, ethoxylated (40 mol EO average molar ratio)
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における PEG-40水添ヒマシ油 (PEG-40 HYDROGENATED CASTOR OIL) のグローバル配合基準と処方特性とは?

PEG-40水添ヒマシ油(標準 INCI: PEG-40 HYDROGENATED CASTOR OIL、CAS番号: 61788-85-0)は、化粧品処方において主に乳化剤, 洗浄剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 0.5–6%(適正安定域 pH 4–8)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for PEG-40 HYDROGENATED CASTOR OIL
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)PEG-40 HYDROGENATED CASTOR OIL (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)PEG-40 HYDROGENATED CASTOR OIL
④ 米国一般化粧品 (US PCPC / MoCRA INCI)PEG-40 HYDROGENATED CASTOR OIL
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)PEG-40 氢化蓖麻油
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)PEG-40水添ヒマシ油 · [QD: ポリオキシエチレン硬化ヒマシ油]

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for PEG-40 HYDROGENATED CASTOR OIL
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #681
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for PEG-40 HYDROGENATED CASTOR OIL
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 10%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 00462 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 8%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 00462 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Rinse-off Cleansern=9
Min 0.5% · Q1 0.5% · Median 1% · Q3 3.7% · Max 6%
Rinse-off Cleanser — Rinse-off cleanser & surfactant system modifier
Verified Source: Global Starter Formulation Library Statistical Distribution (n=9, EVONIK 9) (cir_safety) · EVONIK 9
Typical Median: 1%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for PEG-40 HYDROGENATED CASTOR OIL
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 C — 洗い流し用クレンザー・シャンプー0.5% · 0.5% · 1% · 3.7% · 6%Rinse-off cleanser & surfactant system modifierGlobal Starter Formulation Library Statistical Distribution (n=9, EVONIK 9)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…PEG-40 HYDROGENATE…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
PEG-40 HYDROGENATED CASTOR OIL

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: PEG-40 HYDROGENATED CASTOR OIL | CAS No.: 61788-85-0 | EC No.: N/A - Origin: SYNTHETIC | Functions: , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [PEG-40 HYDROGENATED CASTOR OIL] · EU [PEG-40 HYDROGENATED CASTOR OIL] · CN [PEG-40 氢化蓖麻油] · JP [PEG-40水添ヒマシ油] · JP Quasi-Drug [ポリオキシエチレン硬化ヒマシ油] ■ [2. Dermatological Mechanism of Action & Functional Role] - Castor oil (Ricinus communis), hydrogenated, ethoxylated (40 mol EO average molar ratio) Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 681 (PEG-40 氢化蓖麻油)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 10.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 8.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [cleanser_rinse] Typical range: 0.5 ~ 6.0% (Median 1.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=9, EVONIK 9)) — Rinse-off cleanser & surfactant system modifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: PEG-40 HYDROGENATED CASTOR OIL ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 35335897 (2022, Pharmaceutics): Facile Solvent-Free Preparation of Antioxidant Idebenone-Loaded Nanoparticles for Efficient Wound Healing. - PMID 39502637 (2024, Int J Nanomedicine): Penetration Enhancer-Free Mixed Micelles for Improving Eprinomectin Transdermal c Efficiency in Animal Parasitic Infecti - PMID 22579578 (2012, Int J Pharm): Investigation of surfactant/cosurfactant synergism impact on ibuprofen solubilization capacity and drug release characte

関連査読付き学術論文 (NIH PubMed) (4)

Facile Solvent-Free Preparation of Antioxidant Idebenone-Loaded Nanoparticles for Efficient Wound Healing. [PMID: 35335897 · 2022]
Yang H, Yu S, Kim J, Baek K, Lee YR, Lee HS, Choi WI, Sung D · Pharmaceutics (2022)

The excessive production of reactive oxygen species (ROS) causes harmful effects, including biomolecular damage and inflammation. ROS due to ultraviolet rays, blue light, and fine dust harm the skin, causing urban-related aging. Therefore, a strong antioxidant that relieves oxidative stress in the skin and removes ROS is required. Idebenone (IB) is a powerful antioxidant but is poorly soluble and thus has low solubility in water, resulting in low bioavailability. In this study, IB-loaded nanoparticles (IB@NPs) were synthesized by loading IB without an organic solvent into nanoparticles that can provide high loading efficiency and stability for solubilization. Indeed, the synthesized IB@NPs exhibited long-term stability through dynamic light scattering, methylene blue staining, and redispersion assays, and IB@NPs prepared with a 5 wt% IB loading content were found to be optimal. The antioxidant activity of IB@NPs evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was significantly higher than that of unloaded IB. In addition, IB@NPs showed excellent biocompatibility, inhibited oxidative damage to mouse NIH-3T3 fibroblasts, and reduced intracellular ROS generation according to an in vitro DPPH antioxidant assay. Most notably, IB@NPs significantly promoted wound healing in vitro, as demonstrated by scratch assays. Therefore, as carriers with excellent stability, IB@NPs have potential cosmetic and pharmaceutical applications.

Penetration Enhancer-Free Mixed Micelles for Improving Eprinomectin Transdermal c Efficiency in Animal Parasitic Infections Therapy. [PMID: 39502637 · 2024]
Mao Y, Hao T, Zhang H, Gu X, Wang J, Shi F, Chen X, Guo L, Gao J, Shen Y, Zhang J, Yu S · Int J Nanomedicine (2024)

Eprinomectin offers promise against parasitic infections. This study develops Eprinomectin (EPR) mixed micelles for transdermal delivery, aiming to enhance efficacy and convenience against endoparasites and ectoparasites. Physicochemical characterization and pharmacokinetic studies were conducted to assess its potential as an effective treatment for parasitic infections. Blank and EPR mixed micelles were prepared using PEG-40 Hydrogenated castor oil (RH-40) and Nonyl phenol polyoxyethylene ether 40 (NP-40). Critical micelle concentrations (CMC) determined using the pyrene fluorescence probe method. Particle size, EE, DL, in vitro release, permeation, and skin irritation were evaluated. In vivo pharmacokinetic studies were conducted in male Sprague-Dawley rats. Results show that EPR mixed micelles present suitable stability, physicochemical properties, and safety. Moreover, the rapid release and high bioavailability of EPR mixed micelles have also been verified in the study. Pharmacokinetic experiments in vivo showed that an improvement in the transdermal absorption and bioavailability of EPR after encapsulation in mixed micelles formulations. The results proved that the novel mixed micelles are safe and effective and are expected to become a promising veterinary nano-delivery system.

Investigation of surfactant/cosurfactant synergism impact on ibuprofen solubilization capacity and drug release characteristics of nonionic microemulsions. [PMID: 22579578 · 2012]
Djekic L, Primorac M, Filipic S, Agbaba D · Int J Pharm (2012)

The current study investigates the performances of the multicomponent mixtures of nonionic surfactants regarding the microemulsion stabilisation, drug solubilization and in vitro drug release kinetic. The primary surfactant was PEG-8 caprylic/capric glycerides (Labrasol). The cosurfactants were commercially available mixtures of octoxynol-12 and polysorbate 20 without or with the addition of PEG-40 hydrogenated castor oil (Solubilisant gamma 2421 and Solubilisant gamma 2429, respectively). The oil phase of microemulsions was isopropyl myristate. Phase behaviour study of the pseudo-ternary systems Labrasol/cosurfactant/oil/water at surfactant-to-cosurfactant weight ratios (K(m)) 40:60, 50:50 and 60:40, revealed a strong synergism in the investigated tensides mixtures for stabilisation of microemulsions containing up to 80% (w/w) of water phase at surfactant +cosurfactant-to-oil weight ratio (SCoS/O) 90:10. Solubilization of a model drug ibuprofen in concentration common for topical application (5%, w/w) was achieved at the water contents below 50% (w/w). Drug free and ibuprofen-loaded microemulsions M1-M6, containing 45% (w/w) of water phase, were prepared and characterized by polarized light microscopy, conductivity, pH, rheological and droplet size measurements. In vitro ibuprofen release kinetics from the microemulsions was investigated using paddle-over-enhancer cell method and compared with the commercial 5% (w/w) ibuprofen hydrogel product (Deep Relief, Mentholatum Company Ltd., USA). The investigated microemulsions were isotropic, low viscous Bingham-type liquids with the pH value (4.70-6.61) suitable for topical application. The different efficiency of the tensides mixtures for microemulsion stabilisation was observed, depending on the cosurfactant type and K(m) value. Solubilisant gamma 2429 as well as higher K(m) (i.e., lower relative content of the cosurfactant) provided higher surfactant/cosurfactant synergism. The drug molecules were predominantly solubilized within the interface film. The amount of drug released from the formulations M3 (10.75%, w/w) and M6 (13.45%, w/w) (K(m) 60:40) was limited in comparison with the reference (22.22%, w/w) and follows the Higuchi model. Microemulsions M2 and M5 (K(m) 50:50) gave zero order drug release pattern and &#x223c;15% (w/w) ibuprofen released. The release profiles from microemulsions M1 and M4 (K(m) 40:60) did not fit well with the models used for analysis, although the amounts of ibuprofen released (24.47%, w/w) and 17.99% (w/w), respectively) were comparable to that of the reference hydrogel. The drug release mechanism was related with the surfactant/cosurfactant synergism, thus the lower efficiency of the tensides corresponded to the faster drug release.

Formulation of lyotropic liquid crystal containing mulberry stem extract: influences of formulation ingredients on the formation and the nanostructure. [PMID: 24471700 · 2014]
Yhirayha C, Soontaranon S, Wittaya-Areekul S, Pitaksuteepong T · Int J Cosmet Sci (2014)

This study focused on the formulation of lamellar lyotropic liquid crystal (LLC) loaded with mulberry stem extract (MSE). The LLC formulation tested used two oils: n-dodecane or tridecyl salicylate, a co-solvent (propylene glycol) and a single (PEG-7 glyceryl cocoate) or mixed surfactant system. The mixed surfactant was PEG-7 glyceryl cocoate/PEG-40 hydrogenated castor oil/glyceryl monooleate. The LLC formation and phase behaviour were observed by polarized optical microscopy (POM) before and after MSE loading. Nanostructure determinations on these formulations following MSE loading used small angle X-ray scattering (SAXS) at 25-40&#xb0;C. Lamellar LLCs are formed more easily with n-dodecane than tridecyl salicylate. Propylene glycol, in the aqueous phase (1 : 1), failed to form LLC due to suboptimal critical packing parameter (CPP) value. A single or mixed surfactant system also influenced the formation of lamellar LLC according to the chemical structure of both oils and especially the surfactants used. The four lamellar LLC formulations selected for MSE loading were PEG-7 glyceryl cocoate/tridecyl salicylate/water; mixed surfactant/tridecyl salicylate/water; PEG-7 glyceryl cocoate/n-dodecane/water and mixed surfactant/n-dodecane/water, named F1, F2, F3 and F4, respectively. MSE in F1 and F3 did not affect the lamellar structure, while MSE in F2 and F4 enlarged the lamellar structure. The SAXS data confirmed that the LLC formulations obtained were lamellar and the structure persisted with MSE. These lamellar formulations should find widespread application for MSE and perhaps other similar herbal cosmetics.

よくある質問 (FAQ)

Q1. PEG-40水添ヒマシ油 (PEG-40 HYDROGENATED CASTOR OIL) の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'PEG-40水添ヒマシ油'、米国PCPC・欧州CosIng INCIは 'PEG-40 HYDROGENATED CASTOR OIL'、中国NMPA IECIC標準中国語名は 'PEG-40 氢化蓖麻油' です。
Q2. PEG-40水添ヒマシ油 (PEG-40 HYDROGENATED CASTOR OIL) のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における PEG-40水添ヒマシ油 (PEG-40 HYDROGENATED CASTOR OIL) の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (cleanser_rinse) において通常 0.5〜6%(中央値 1%)で配合され、適正pH範囲は 4〜8 です。
Q4. PEG-40水添ヒマシ油 (PEG-40 HYDROGENATED CASTOR OIL) の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。